November 04, 2025

FDA Approves First Drug for Thymidine Kinase 2 Deficiency

First-ever treatment shows significant survival benefit in matched-pair analysis of this ultra-rare mitochondrial depletion syndrome.

Conexiant

October 31, 2025

Single-Injection Omvoh Option Simplifies Ulcerative Colitis Care

The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 28, 2025

Insurance Shake-Up: Who Loses Out?

Families nationwide face rising health insurance costs as Affordable Care Act subsidies near expiration, with premiums and deductibles projected to increase amid congressional inaction.

KFF Health News

October 22, 2025

Fall Vaccines: What’s New, What’s Not

Updated CDC fall vaccine guidance simplifies covid, flu, and RSV shots with broad access and minimal changes from last year.

KFF Health News

October 22, 2025

FDA Redefining Depression Treatment with New Approvals?

Researchers analyze FDA-approved and Phase 3 antidepressants from 2009 to 2025.

Conexiant

October 20, 2025

Which Hair Loss Treatments Truly Deliver Results?

Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density.

Conexiant

October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant